The U.S. Food and Drug Administration has approved a new medicine called Krystexxa (pegloticase) for adults with chronic gout that has not responded to standard treatments. Gout is a form of arthritis caused by too much uric acid in the blood, which can form sharp crystals in joints, causing sudden pain and swelling. Krystexxa works by breaking down uric acid, helping to lower its levels in the body.
This drug is specifically for people with severe, refractory gout, meaning their condition has not improved with other medications like allopurinol or febuxostat, or they cannot take those drugs. It is not meant for people who simply have high uric acid without symptoms. Krystexxa is given as an intravenous infusion every two weeks, and it is often combined with methotrexate to reduce the risk of the body rejecting the drug.
Because Krystexxa can cause serious allergic reactions, including anaphylaxis, it must be given in a healthcare setting where staff are prepared to handle emergencies. Patients also receive premedication with antihistamines and steroids before each infusion. Doctors will check uric acid levels before each dose and stop the treatment if levels rise, as that may indicate a loss of response and a higher risk of reactions.
This approval provides a new option for a group of patients who previously had very few choices. If you have chronic gout and think Krystexxa might be right for you, talk to your doctor. They can help you understand the potential benefits and risks, and whether this treatment fits your specific situation.
